ORIGINAL RESEARCH ARTICLE

Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality

Heerajnarain Bulluck, Raju Maiti, Bibhas Chakraborty, Luciano Candilio, Tim Clayton, Richard Evans, David P Jenkins, Shyam Kolvekar, Gudrun Kunst, Christopher Laing, Jennifer Nicholas, John Pepper, Derek M Yellon, Derek J Hausenloy

ABSTRACT

Objective We aimed to investigate whether preoperative serum neutrophil gelatinase-associated lipocalin (sNGALpre-op) predicted postoperative acute kidney injury (AKI) during hospitalisation and 1-year cardiovascular and all-cause mortality following adult cardiac surgery.

Methods This study was a post hoc analysis of the Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Patient Undergoing Coronary Artery Bypass Graft Surgery trial involving adult patients undergoing coronary artery bypass graft. Postoperative AKI within 72 hours was defined using the International Kidney Disease: Improving Global Outcomes classification.

Results 1371 out of 1612 patients had data on sNGALpre-op. The overall 1-year cardiovascular and all-cause mortality was 5.2% (71/1371) and 7.7% (105/1371), respectively. There was an observed increase in the incidence of AKI from the first to the third tertile of sNGALpre-op (30.5%, 41.5% and 45.9%, respectively, p<0.001). There was also an increase in both cardiovascular and all-cause mortality from the first to the third tertile of sNGALpre-op linear trend test with adjusted p=0.018 and p=0.013, respectively. The adjusted HRs for those in the second and third tertiles of sNGALpre-op compared with the first tertile were 1.60 (95% CI 0.78 to 3.25) and 2.22 (95% CI 1.13 to 4.35) for cardiovascular mortality, and 1.25 (95% CI 0.71 to 2.22) and 1.91 (95% CI 1.13 to 3.25) for all-cause mortality at 1 year.

Conclusion In a cohort of high-risk adult patients undergoing cardiac surgery, there was an increase in postoperative AKI and 1-year mortality from the first to the third tertile of preoperative serum NGAL. Those in the last tertile (>220 ng/L) had an estimated twofold increase risk of cardiovascular and all-cause mortality at 1 year.

Clinical trial registration NCT01247545; Post-results.

INTRODUCTION

Acute kidney injury (AKI) occurs in up to 30% of adult patients undergoing cardiac surgery, and its presence is associated with worse short-term and long-term morbidity and mortality. Even mild to moderate increases in serum creatinine following cardiac surgery are associated with higher 30-day mortality. Around a fifth of patients with AKI will go on to require renal replacement therapy, and this subgroup has the worst prognosis with in-hospital mortality rates up to 60%. The development of AKI is multifactorial, and the underlying mechanisms remain unclear, although acute tubular necrosis is assumed to be the predominant pathology. Although several tools have been developed to predict the development of AKI prior to cardiac surgery, they have been predominantly designed to predict severe AKI requiring dialysis. More work remains to be done to improve the identification of those at risk of even milder grades of AKI prior to cardiac surgery.

Neutrophil gelatinase-associated lipocalin (NGAL) belongs to the lipocalin family and is produced predominantly by the liver and white blood cells. It is released excessively in the blood and in the urine after injury to the kidney tubules. NGAL has previously been termed the ‘troponin-like’ biomarker to detect AKI, but after promising results in children undergoing cardiac surgery, it has not performed as well for the early detection of AKI in adults. This can be partly explained by the fact that NGAL is not specific for the kidney injury, as it can also be released during sepsis, inflammation and acute exacerbations of chronic illnesses, and therefore it remains a research tool.

Most recently, preoperative plasma NGAL has been shown to be independently associated with 3-year mortality following adult cardiac surgery. There are some conflicting reports on whether preoperative plasma NGAL can predict postoperative AKI, but those studies were underpowered. Therefore, we aimed to investigate whether preoperative serum NGAL (sNGALpre-op) predicted both postoperative AKI during hospitalisation and 1-year cardiovascular and all-cause mortality in adults undergoing cardiac surgery.

METHODS

The current study was a post hoc analysis of the Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Patient Undergoing Coronary Artery Bypass Graft Surgery (ERICCA) (NCT01247545), the trial design and results of which have been...
Coronary artery disease

previously published.\textsuperscript{19, 20} In brief, 1612 patients were prospectively recruited in this multicentre, randomised controlled trial between April 2011 and March 2014 but only those with data on sNGAL\textsubscript{pre-op} were included in this analysis (n=1371). The inclusion criteria were adults aged \(\geq 18\) years of age and with an additive European System for Cardiac Operative Risk Evaluation (EuroSCORE) \(\geq 5\) (high risk), undergoing on-pump coronary artery bypass grafting (CABG) with or without valve surgery, with blood cardioplegia. Those with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m\(^2\) were excluded. They were randomised to remote ischaemic conditioning (RIC) or sham preconditioning. The clinical endpoints collected were cardiovascular death and all-cause mortality at 1 year, non-fatal myocardial infarction, coronary revascularisation or stroke at 1 year and AKI within 72 hours followingsurgery as defined by the International Kidney Disease: Improving Global Outcomes classification (KDIGO).\textsuperscript{21} There was no difference in the incidence of AKI between those who were randomised to RIC or sham. Serum NGAL was measured from blood collected in serum-separating tubes preoperatively using CircuLex NGAL/Lipocalin 2 ELISA. The study was approved by the National Health Service Research Ethics Committee, and all patients provided informed written consent.

AKI within 72 hours was graded as none, 1, 2, 3 as per the KDIGO criteria as follows: grade 1: serum creatinine 1.5–1.9 times baseline or an increase in serum creatinine \(\geq 26.5\) \(\mu\)mol/L; grade 2: serum creatinine 2.0–2.9 times baseline; and grade 3: serum creatinine 3.0 times baseline or increase in serum creatinine to \(\geq 353.6\) \(\mu\)mol/L or initiation of renal replacement therapy. The primary outcomes of interest were any AKI grade during hospitalisation and cardiovascular and all-cause mortality at 1 year.

Statistical analysis
Statistical analysis was performed using SPSS V23. sNGAL\textsubscript{pre-op} was analysed as tertiles. Continuous data were expressed as means and SD or medians and (first quartile–third quartile), and categorical data were reported as frequencies and percentages. Unadjusted associations of the tertiles of sNGAL\textsubscript{pre-op} with other baseline and procedure variables were performed using one-way analysis of variance or Kruskal-Wallis test where appropriate. Logistic regression analysis was performed to assess whether sNGAL\textsubscript{pre-op} was an independent predictor any grade of AKI (as a binary outcome), after adjusting for known preoperative predictors of AKI (age, gender, diabetes mellitus, hypertension, peripheral vascular disease (PVD), previous CABG, type of surgery planned, use of intra-aortic balloon pump, baseline eGFR, baseline left ventricular ejection fraction (LVEF) category and preoperative high sensitivity troponin T).\textsuperscript{22} This analysis was performed using tertiles of sNGAL\textsubscript{pre-op}, as previously done,\textsuperscript{16} to allow findings to be more easily translated to the clinical setting. Kaplan-Meier curves were used to assess survival at 1 year per tertile. The primary analysis for the cumulative incidence of cardiovascular and all-cause mortality at 1 year was performed using Cox proportional hazard (with censoring of data to the date of occurrence of the primary endpoint, lost to follow-up, withdrawal from the study or at 1 year), and the HRs were computed with 95% CI after adjusting for the factors that were present in both EuroSCORE II\textsuperscript{23} and the Society of Thoracic Surgeon (STS) score\textsuperscript{24} that were available from our cohort (namely age, gender, eGFR, PVD, previous stroke, previous CABG, baseline LVEF category, diabetes mellitus, use of intra-aortic balloon pump, type of surgery planned and preoperative high sensitivity troponin T).

RESULTS
Out of 1612 patients recruited in the ERICCA trial, 1371 patients had sNGAL\textsubscript{pre-op} measured. These patients had a mean age of 76.0±6.6 years and 27.5% were female. As expected, they were in the high-risk category for cardiac surgery with a median additive EuroSCORE of 6 (5–7). Further details of the baseline characteristics of these 1371 patients per tertile are provided in table 1. The overall all-cause mortality and cardiovascular mortality was 7.7% (105/1371) and 5.2% (71/1371), respectively. AKI data were available in 97% (1330/1371) of patients. AKI during the initial hospitalisation occurred in 39.6% of patients (31.2% AKI grade 1). The median sNGAL\textsubscript{pre-op} was 175 (117–257) ng/L and range of 27–3171 ng/L. sNGAL\textsubscript{pre-op} was divided into three groups according to tertiles <135 ng/L, 135–<220 ng/L and ≥220 ng/L. There was no difference in the prevalence of diabetes mellitus, hypertension, dyslipidaemia and vascular disease among the three tertiles as shown in table 1. Furthermore, there was no difference in the type of surgery or duration of the cardiopulmonary bypass and cross-clamp times. However, patients in the higher tertiles were more likely to be older, of the male gender, have higher baseline creatinine and eGFR and spend longer time on intensive care unit and in hospital. The cardiovascular and all-cause mortality at 1 year per tertile and per the presence or absence of AKI are summarised in table 2.

sNGAL\textsubscript{pre-op} and AKI
On a per-tertile basis, there was an increase in the incidence of AKI with increasing tertile of sNGAL\textsubscript{pre-op} from 30.5% in the first tertile, 41.5% in the second tertile and 45.9% in the third tertile. Using the first tertile of sNGAL\textsubscript{pre-op} as reference, multivariable analysis showed that the second tertile of sNGAL\textsubscript{pre-op} had an OR of 1.69 (95% CI 1.23 to 2.30), and the third tertile of sNGAL\textsubscript{pre-op} had an OR of 1.53 (95% CI 1.12 to 2.10), p=0.009 for linear trend test, to predict AKI, after adjusting for known preoperative predictors of AKI.

Receiver operating characteristic (ROC) curve analysis showed that sNGAL\textsubscript{pre-op} was a predictor of AKI, but the c-statistic was only 0.57 (95% CI 0.54 to 0.61). The c-statistic improved to 0.69 (95% CI 0.66 to 0.73) (p<0.001 for ROC curves comparison) when age, gender, diabetes mellitus, hypertension, PVD, previous CABG, type of surgery planned, use of intra-aortic balloon pump, baseline eGFR, baseline ejection fraction and baseline high sensitivity troponin T were included in the model together with tertiles of sNGAL\textsubscript{pre-op} as shown in figure 1.

AKI and mortality
Patients with AKI had a higher mortality at 1 year with an all-cause mortality rate of 12.1% versus 4.1% (table 2), when compared with those without AKI with an adjusted HR (adjusted for the above EuroSCORE II and STS-derived preoperative predictors of mortality) of 2.67 (95% CI 1.72 to 4.13), adjusted p<0.001 from the Cox regression analysis. Those with AKI also had worse cardiovascular mortality at 1 year with a mortality rate of 7.8% versus 2.7%, when compared with those without AKI, with an adjusted HR of 2.88 (95% CI 1.67 to 4.98), adjusted p<0.001 from the Cox regression analysis.

sNGAL\textsubscript{pre-op} and mortality
After a follow-up of 12 months, 5.5% of patients in the first tertile died, compared with 7.0% in the second tertile and 10.5% of the patients in the third tertile as summarised in table 2. There was an increase in both cardiovascular and all-cause mortality

from the first to the third tertile of sNGAL_{pre-op}, linear trend test with adjusted p=0.018 and p=0.013, respectively. With sNGAL_{pre-op} in the first tertile as the reference, the adjusted HR (adjusted for the above EuroSCORE II and STS-derived preoperative predictors of mortality) for those in the second and third tertiles of sNGAL_{pre-op} were 1.60 (95% CI 0.78 to 3.25) and 2.22 (95% CI 1.13 to 4.35) for cardiovascular mortality, and 1.25 (95% CI 0.71 to 2.22) and 1.91 (95% CI 1.13 to 3.25) for all-cause mortality at 1 year. Figure 2 shows the Kaplan-Meier curves for 1-year all-cause mortality according to tertiles of sNGAL_{pre-op}.

**DISCUSSION**

The major findings of this study of high-risk patients undergoing cardiac surgery were as follows: (1) preoperative serum levels of NGAL predicted postoperative AKI, after accounting for preoperative clinical parameters (age, gender, diabetes mellitus, hypertension, PVD, previous CABG, type of surgery planned, use of intra-aortic balloon pump, baseline eGFR, baseline ejection fraction and baseline high sensitivity troponin T), with the performance of sNGAL_{pre-op} to predict AKI improving when these clinical parameters were included in the model; (2) tertiles of sNGAL_{pre-op} were associated with mortality after adjusting for confounders, with those in the third tertile having a twofold increase in the hazard for cardiovascular and all-cause mortality; (3) the overall incidence of postoperative AKI in this cohort was 39.6% and was as high as 45.9% for those in the third tertile of sNGAL_{pre-op}; (4) the presence of AKI was associated with mortality, and in our cohort, there was more than

**Table 1** Characteristics of patients according to tertiles of sNGAL_{pre-op}

<table>
<thead>
<tr>
<th>sNGAL_{pre-op}</th>
<th>n=1371</th>
<th>First tertile 135 –&lt;135 ng/L (n=457)</th>
<th>Second tertile 135 –&lt;220 ng/L (n=456)</th>
<th>Third tertile &gt;220 ng/L (n=458)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age/years</td>
<td></td>
<td>75.4±7.0</td>
<td>76.1±6.1</td>
<td>76.6±6.6</td>
<td>0.03</td>
</tr>
<tr>
<td>Male (n (%))</td>
<td></td>
<td>302 (66.2)</td>
<td>342 (75.3)</td>
<td>345 (75.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Additive EuroSCORE</td>
<td></td>
<td>6 (5–7)</td>
<td>6 (5–7)</td>
<td>6 (5–8)</td>
<td>0.03</td>
</tr>
<tr>
<td>BMI/kg/m²</td>
<td></td>
<td>27.2±4.3</td>
<td>27.8±4.5</td>
<td>27.7±4.4</td>
<td>0.08</td>
</tr>
<tr>
<td>Current smoker (n (%))</td>
<td></td>
<td>26 (5.7)</td>
<td>28 (6.2)</td>
<td>24 (5.3)</td>
<td>0.45</td>
</tr>
<tr>
<td>Diabetes mellitus (n (%))</td>
<td></td>
<td>112 (24.6)</td>
<td>119 (26.2)</td>
<td>124 (27.3)</td>
<td>0.65</td>
</tr>
<tr>
<td>Dyslipidaemia (n (%))</td>
<td></td>
<td>321 (70.4)</td>
<td>331 (72.9)</td>
<td>316 (69.5)</td>
<td>0.50</td>
</tr>
<tr>
<td>Hypertension (n (%))</td>
<td></td>
<td>345 (75.7)</td>
<td>340 (74.9)</td>
<td>353 (77.6)</td>
<td>0.62</td>
</tr>
<tr>
<td>Previous MI (n (%))</td>
<td></td>
<td>166 (36.4)</td>
<td>189 (41.6)</td>
<td>197 (43.3)</td>
<td>0.09</td>
</tr>
<tr>
<td>Atrial fibrillation (n (%))</td>
<td></td>
<td>70 (15.4)</td>
<td>71 (15.6)</td>
<td>82 (18.0)</td>
<td>0.49</td>
</tr>
<tr>
<td>PVD (n (%))</td>
<td></td>
<td>40 (8.8)</td>
<td>32 (7.0)</td>
<td>37 (8.1)</td>
<td>0.63</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td>51 (11.2)</td>
<td>53 (11.7)</td>
<td>51 (11.2)</td>
<td>0.97</td>
</tr>
<tr>
<td>LVEF category (n (%))</td>
<td></td>
<td>Good</td>
<td>Moderate</td>
<td>Poor</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>300 (68.8)</td>
<td>296 (67.6)</td>
<td>276 (63.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>89 (20.4)</td>
<td>93 (21.2)</td>
<td>103 (23.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>47 (10.8)</td>
<td>49 (11.2)</td>
<td>55 (12.7)</td>
<td></td>
</tr>
<tr>
<td>Baseline creatinine/µmol/L</td>
<td></td>
<td>83 (73–97)</td>
<td>91 (76–108)</td>
<td>95 (80–118)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>eGFR at baseline/ml/min/1.73 m²</td>
<td></td>
<td>75 (62–90)</td>
<td>71 (59–85)</td>
<td>67 (53–82)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cardiopulmonary bypass time/hour</td>
<td></td>
<td>1.75 (1.39–2.20)</td>
<td>1.72 (1.33–2.23)</td>
<td>1.77 (1.35–2.35)</td>
<td>0.34</td>
</tr>
<tr>
<td>Cross-clamp time/hour</td>
<td></td>
<td>1.17 (0.80–1.55)</td>
<td>1.12 (0.78–1.57)</td>
<td>1.15 (0.83–1.63)</td>
<td>0.26</td>
</tr>
<tr>
<td>CABG only (n (%))</td>
<td></td>
<td>229 (50.2)</td>
<td>243 (53.3)</td>
<td>228 (50.1)</td>
<td>0.55</td>
</tr>
<tr>
<td>CABG+valve surgery (n (%))</td>
<td></td>
<td>227 (49.8)</td>
<td>213 (46.7)</td>
<td>227 (49.9)</td>
<td></td>
</tr>
<tr>
<td>Length of ITU stay</td>
<td></td>
<td>2 (1–4)</td>
<td>3 (1–5)</td>
<td>3 (1–5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Length of hospital stay</td>
<td></td>
<td>9 (7–14)</td>
<td>10 (7–16)</td>
<td>12 (8–21)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AKI (any) (n (%))</td>
<td></td>
<td>135 (30.5)</td>
<td>186 (41.5)</td>
<td>206 (45.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PMI</td>
<td></td>
<td>112 (24.5)</td>
<td>102 (22.4)</td>
<td>118 (25.8)</td>
<td>0.48</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td>11 (2.4)</td>
<td>5 (1.1)</td>
<td>7 (1.5)</td>
<td>0.29</td>
</tr>
<tr>
<td>Revascularisation</td>
<td></td>
<td>1 (0.2)</td>
<td>3 (0.7)</td>
<td>2 (0.4)</td>
<td>0.60</td>
</tr>
</tbody>
</table>

AKI, acute kidney injury; BMI, body mass index; CABG, coronary artery bypass graft surgery; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; ITU, intensive care unit; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PMI, perioperative myocardial infarction; PVD, peripheral vascular disease; RIC, remote ischaemic conditioning; sNGAL_{pre-op}, preoperative serum neutrophil gelatinase-associated lipocalin.

**Table 2** One-year cardiovascular and all-cause mortality rates per tertiles of sNGAL_{pre-op} and per presence or absence of AKI

<table>
<thead>
<tr>
<th></th>
<th>First Tertile 135 –&lt;135 ng/L (n=457)</th>
<th>Second Tertile 135 –&lt;220 ng/L (n=456)</th>
<th>Third Tertile &gt;220 ng/L (n=458)</th>
<th>Adjusted p value</th>
<th>No AKI (n=803)</th>
<th>AKI (n=527)</th>
<th>Adjusted p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-year cardiovascular mortality</td>
<td>3.5% (16)</td>
<td>5.3% (24)</td>
<td>6.8% (31)</td>
<td>0.018</td>
<td>2.7% (22)</td>
<td>7.8% (41)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1-year all-cause mortality</td>
<td>5.5% (25)</td>
<td>7.0% (32)</td>
<td>10.5% (48)</td>
<td>0.013</td>
<td>4.1% (33)</td>
<td>12.1% (64)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

AKI, acute kidney injury; sNGAL_{pre-op}, preoperative serum neutrophil gelatinase-associated lipocalin.
twofold increase in both cardiovascular and all-cause mortality at 1 year.

The performance of the model to predict AKI was improved when clinical parameters were included in addition to sNGAL-pre-op, but the c-statistic was only increased to 0.69. Other risk scores to predict AKI have had c-statistics ranging between 0.72 and 0.84, but most of them were designed to predict worse grades of AKI.2 Therefore, Huen et al5 recently concluded that more studies are required to develop risk models to predict milder forms of AKI after cardiac surgery in a systematic review of existing risk scores. However, our study included high-risk patients with EuroSCORE ≥5 only and whether by applying the same approach of using sNGAL-pre-op with clinical parameters to predict any grades of AKI would yield a higher diagnostic performance warrants further investigation.

Postoperative urinary NGAL,25 in contrast to postoperative plasma NGAL, has been shown to be associated with all-cause 3-year mortality. Whether pNGAL-pre-op could predict AKI and mortality has also been investigated. Haase-Fieltz et al17 found no difference in preoperative serum NGAL between those who developed AKI when compared with those who did not. However, this study only included 100 patients and did not have mortality data. However, Doi et al16 showed that preoperative plasma NGAL was an independent risk factor for postoperative AKI in 146 patients. A larger study of 1191 patients showed that preoperative plasma NGAL was a predictor of 3-year mortality, but the relationship between NGAL and AKI was not assessed.16 In the general population, baseline plasma NGAL has also been shown to be associated with 10-year cardiovascular mortality.26 In a cohort of community-dwellers with a mean age of 70 years, plasma NGAL was a significant predictor of mortality, independent of traditional risk factors and renal function.27 We have shown in a larger cohort of high-risk patients that sNGAL-pre-op was a predictor of both AKI following cardiac surgery, as well as a predictor of 1-year cardiovascular and all-cause mortality, after adjusting for known preoperative predictors of AKI. Therefore, sNGAL-pre-op could complement existing tools to risk-stratify patients prior to cardiac surgery.

AKI has typically been reported to occur in up to 30%1,2 of patients undergoing adult cardiac surgery, but the incidence of AKI in our cohort was higher at 39.6%. This may be explained by the inclusion of patients with an additive EuroSCORE of ≥5 and therefore representative of the incidence of AKI in a high-risk cohort.

Limitations

Our cohort may not be representative of the wider population of patients undergoing CABG surgery as these patients were included in a randomised controlled trial. There are currently no established cut-off values as shown by the study by Moledina et al,16 which used cut-off values of 155 ng/L and 251 ng/L for the tertiles and we used 130 ng/L and 220 ng/L. Although intraoperative factors play a role in the development of postoperative AKI, we only looked at preoperative factors as the aim of this study was to assess the ability of sNGAL-pre-op to identify those at higher risk of AKI and mortality prior to surgery. Ten per cent of the cases had missing data when it came to performing the analysis for the adjusted models. We did not specifically collect data on sepsis or exacerbation of chronic illness prior to surgery, which are known confounders for elevated NGAL levels. However, these patients were

**Key messages**

**What is already known about this subject?**
The development of acute kidney injury following adult cardiac surgery is associated with short-term and long-term morbidity and mortality.

**What are the new findings?**
Preoperative serum neutrophil gelatinase-associated lipocalin was an independent predictor of postoperative acute kidney injury and 1-year mortality.

**How might these results change the focus of research or clinical practice?**
Preoperative serum neutrophil gelatinase-associated lipocalin could be used on top of existing risk scores to further risk-stratify those at higher risk of postoperative acute kidney injury and 1-year mortality.
CONCLUSIONS
In a cohort of high-risk adult patients undergoing cardiac surgery, preoperative serum NGAL was an independent predictor of postoperative AKI and 1-year cardiovascular and all-cause mortality. Those in the third tertile of preoperative serum NGAL (≥220 ng/L) had a twofold increase risk of postoperative AKI and mortality at 1 year. This risk stratification of patients prior to cardiac surgery may be improved by adding preoperative serum NGAL to existing risk scores for AKI and mortality and warrants further investigations.

REFERENCES
Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality

Heerajnarain Bulluck, Raju Maiti, Bibhas Chakraborty, Luciano Candilio, Tim Clayton, Richard Evans, David P Jenkins, Shyam Kolvekar, Gudrun Kunst, Christopher Laing, Jennifer Nicholas, John Pepper, Derek M Yellon and Derek J Hausenloy

Heart published online August 9, 2017

Updated information and services can be found at: http://heart.bmj.com/content/early/2017/08/09/heartjnl-2017-311760

These include:

References
This article cites 25 articles, 9 of which you can access for free at: http://heart.bmj.com/content/early/2017/08/09/heartjnl-2017-311760

Open Access
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (254)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/